^
Association details:
| Biomarker: | SETD2 mutation + TP53 mutation |
|---|---|
| Cancer: | Renal Cell Carcinoma |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + Inlyta (axitinib) (VEGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Complete pathologic response to pembrolizumab and axitinib in a patient with sarcomatoid RCC and ocrelizumab-treated multiple sclerosis
Published date:
12/29/2021
Excerpt:
We report a case of sarcomatoid non-clear cell RCC in a patient with underlying multiple sclerosis (MS) on immunosuppression with a complete pathologic response to pembrolizumab and axitinib. Comprehensive genomic profiling revealed pathogenic mutations in SETD2 and TP53...
DOI:
https://doi.org/10.1016/j.urology.2021.12.015
